On October 9, 2020 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, reported that it will present initial data from the ongoing dose escalation portion of its Phase 1 clinical trial of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, in patients with select solid tumors (Press release, Syros Pharmaceuticals, OCT 9, 2020, View Source [SID1234568261]). The data will be presented in a poster session at the 32nd EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium, taking place virtually October 24-25, 2020, and will include data on safety, pharmacokinetics and pharmacodynamics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract is now available on the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) conference website at View Source The presentation will be available for on-demand viewing on the ENA website starting Saturday, Oct. 24, 2020.

Details of the poster presentation are as follows:

Presentation Title: Early evidence of dose-dependent pharmacodynamic activity following treatment with SY-5609, a highly selective and potent oral CDK7 inhibitor, in patients with advanced solid tumors
Session Title: New Drugs
Presenter: Kyriakos P. Papadopoulos, M.D., South Texas Accelerated Research Therapeutics
Abstract Number: 180